Free Trial
NASDAQ:GLMD

Galmed Pharmaceuticals (GLMD) Stock Price, News & Analysis

Galmed Pharmaceuticals logo
$1.44 +0.02 (+1.05%)
As of 01:05 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Galmed Pharmaceuticals Stock (NASDAQ:GLMD)

Key Stats

Today's Range
$1.35
$1.42
50-Day Range
$1.37
$2.33
52-Week Range
$1.15
$23.80
Volume
66,510 shs
Average Volume
1.08 million shs
Market Capitalization
$2.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Galmed Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

GLMD MarketRank™: 

Galmed Pharmaceuticals scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Galmed Pharmaceuticals is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Galmed Pharmaceuticals is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Galmed Pharmaceuticals has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Galmed Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    2.11% of the float of Galmed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Galmed Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Galmed Pharmaceuticals has recently decreased by 66.18%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Galmed Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Galmed Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.11% of the float of Galmed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Galmed Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Galmed Pharmaceuticals has recently decreased by 66.18%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Galmed Pharmaceuticals has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Galmed Pharmaceuticals this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Galmed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Galmed Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.80% of the stock of Galmed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    76.14% of the stock of Galmed Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Galmed Pharmaceuticals' insider trading history.
Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

GLMD Stock News Headlines

Washington Thinks They Own Your Bank Account
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.tc pixel
See More Headlines

GLMD Stock Analysis - Frequently Asked Questions

Galmed Pharmaceuticals' stock was trading at $3.19 at the beginning of 2025. Since then, GLMD shares have decreased by 56.9% and is now trading at $1.3750.

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced its earnings results on Thursday, May, 22nd. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter.

Shares of Galmed Pharmaceuticals reverse split on Monday, May 15th 2023.The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Galmed Pharmaceuticals investors own include Viking Therapeutics (VKTX), OPKO Health (OPK), SCYNEXIS (SCYX), Bristol Myers Squibb (BMY), Plug Power (PLUG), Applied Genetic Technologies (AGTC) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
5/22/2025
Today
8/20/2025
Next Earnings (Estimated)
8/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GLMD
CIK
1595353
Employees
20
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($16.66)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.52 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-32.21%
Return on Assets
-28.59%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.02
Quick Ratio
9.02

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.87 per share
Price / Book
0.15

Miscellaneous

Outstanding Shares
1,650,000
Free Float
1,327,000
Market Cap
$2.38 million
Optionable
Not Optionable
Beta
0.58

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:GLMD) was last updated on 8/20/2025 by MarketBeat.com Staff
From Our Partners